Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neglow
- Development stage
- Unknown
- Lead developer
- Croise Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Neglow is a nutritional supplement and anti-inflammatory combination tablet developed by Croise Pharma. It is formulated with glucosamine (250 mg), chondroitin (250 mg), and methylsulfonylmethane (MSM, 150 mg). These ingredients act synergistically as building blocks for cartilage, helping to stimulate cartilage production, maintain the structural integrity of joints and connective tissues, and protect blood vessels. Neglow is primarily indicated for the management of osteoarthritis, sports injuries, knee pain, and back pain.
- Brand names
- NeglowNeglow Tab
- Other names
- glucosamine + chondroitin + MSMglucosamine + chondroitin + methylsulfonylmethane
Beyond the preview
Go deeper on Neglow.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neglow.